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Neudesin (neuron-derived neurotrophic factor; NENF) was identified as a neurotrophic
factor that is involved in neuronal differentiation and survival. It is abundantly
expressed in the central nervous system, and its neurotrophic activity is exerted via
the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)
pathways. Neudesin is also an anorexigenic factor that suppresses food intake in the
hypothalamus. It is a member of the membrane-associated progesterone receptor (MAPR)
family and shares key structural motifs with the cytochrome b5-like heme/steroid-binding
domain. Progesterone receptor membrane component 1 (PGRMC1), the first to be
discovered among the MAPR family, binds progesterone to induce “rapid non-genomic
effects” in biological responses that are unrelated to the nuclear progesterone receptors
(PRs). Hence, neudesin may also be involved in the rapid non-genomic actions of
progesterone. In this review, we summarize the identification, structure, and activity of
neudesin in the central nervous system, and present an essential overview of the current
understanding of its physiological roles and the prospect of elucidating its non-genomic
progesterone effects.
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INTRODUCTION
Steroid hormones, such as estrogen and progesterone, are known
to exert their physiological effects via their specific nuclear recep-
tors (O’Malley and Means, 1974). Steroid hormones modulate
gene transcription by interacting with these nuclear receptors,
which act as ligand–dependent transcription factors. These effects
are called the “genomic” actions of steroid hormones, which gen-
erally take a few hours to days to manifest fully. However, in some
tissues, including the central nervous system, steroid hormones
have been found to act rapidly (within minutes,) on the tar-
geted cells, independent of their nuclear receptor, suggesting the
possible involvement of unidentified receptors in the rapid non-
genomic actions of steroid hormones (Falkenstein and Wehling,
2000). However, the putative receptors for these actions have not
been identified.
During and after the 1990s, GPR30, one of the typical G-
protein coupled receptors (GPCRs), and membrane progesterone
receptors (mPRs), which are putative GPCRs, were identified as
the membrane receptors for estrogen and progesterone, respec-
tively (Thomas, 2008; Thomas et al., 2009; Prossnitz and Barton,
2011). Moreover, progesterone receptor-membrane component
(PGRMC)1 and PGRMC2, 2 single transmembrane proteins,
were also identified as putative membrane receptors for proges-
terone (Meyer et al., 1996; Cahill, 2007; Peluso, 2007). In contrast
to the nuclear receptors, these membrane receptors mediate rapid
non-genomic effects of the steroid hormones, such as the activa-
tion of mitogen-activated protein kinase (MAPK) signaling and
intracellular Ca2+ increases (Thomas, 2008; Zhu et al., 2008;
Kimura et al., 2012; Figure 1A).
Recently, we identified neudesin (neuron-derived neu-
rotrophic secreted protein) and neuferricin, (neuron-derived
extracellular heme-binding protein, which have high homology
to PGRMC1 and PGRMC2 (Kimura et al., 2005, 2010). These
four proteins (i.e., PGRMC1/2, neudesin, and neuferricin) belong
to the membrane-associated progesterone receptor (MAPR) fam-
ily (Kimura et al., 2012). However, PGRMC1 and PGRMC2 are
located on the cell membrane, whereas neudesin and neuferricin
are secreted proteins. Neudesin potentially promotes neuronal
differentiation and survival in vitro by activating the MAPK
and phosphatidylinositol-3-kinase (PI-3K) signaling pathways
(Kimura et al., 2005, 2006). These effects on cultured neural cells,
together with its expression profiles, suggest that neudesin may
play crucial roles in the development and maintenance of the
central nervous system. Interestingly, neudesin is also reported
to bind to heme by a cytochrome b5-like heme/steroid-binding
domain that is conserved among the MAPR family, and this
binding is essential for the activities of neudesin in vitro (Kimura
et al., 2008). However, the specific receptor for neudesin and the
functional significance of the heme–neudesin interaction have
not yet been clarified.
Since, in various tissues, PGRMC1 is involved in the rapid
non-genomic effects of progesterone, it is expected that neudesin
may also regulate the rapid effects of progesterone. However,
to date, there are no reports on the rapid non-genomic effects
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FIGURE 1 | MAPR family signaling, neudesin homolog in various species,
and multiple sequence alignment of mouse MAPR family. (A) Membrane
progesterone receptor signaling. PR, nuclear progesterone receptor.
(B) Neudesin orthologs of human (NM_013349), cow (NM_001076419),
mouse (NM_025424), rat (NM_001002851), chicken (XM_419430), frog
(NM_001030454), and zebrafish (NM_001037704). The consensus sequence
is shown in red. (C) The cytochrome b5 heme-binding (Cyt-b5) domain is
indicated by the yellow box. Two conserved tyrosine residues, which are
important for heme binding, are shown in red. The predicted signal peptides
of neudesin are shown in blue. (D) Putative neudesin signaling.
of steroid hormones regulated by neudesin. Here, we give an
overview of neudesin, including its identification, expression, and
structural features. In addition, its physiological roles, possible
involvement in progesterone signaling, and future prospects are
discussed.
STRUCTURE
Neudesin cDNAs have been isolated by PCR from embryonic day-
18 mice and from the human brain by PCR (Kimura et al., 2005).
Mouse neudesin cDNA encodes a secretory 171-amino-acid
protein, with a putative signal sequence at its N-terminus. Its
homolog exists in various species, including fish, amphibians,
birds, and vertebrates frommice to humans. To date, the neudesin
gene has not yet been found in invertebrates, includingC. elegans,
D. melanogaster, andC. intestinalis. The N-terminal differs among
mammals and other species, but except for this region, high
amino acid homology exists (Figure 1B). Neudesin contains a
heme/steroid-binding domain that is similar to those of PGRMC1
and cytochrome b5 (Cyt-b5) (Kimura et al., 2008). As mentioned
above, neudesin belongs to the MAPR family, which composed of
PGRMC1, PGRMC2, neudesin, and neuferricin, and is a subfam-
ily of the Cyt-b5 family, which consists of heme-binding proteins
with a Cyt-b5-like heme/steroid-binding domain in their central
regions (Kimura et al., 2012; Figure 1C).
The structure of human neudesin has been obtained by NMR;
it involves a β1-α1-β2-β3-α2-β4-α3-α4-β5-β6 structure that con-
tains 4 α-helices and 6 β-strands, and the heme-binding pocket
is predicted to be formed between α2 and α3 (Han et al.,
2012). The sequence from residues 45–143 in mouse neudesin
is a putative heme-binding domain, in which Tyr-81 and Tyr-87
form the predicted binding site for the heme iron (Figure 1C).
Hence, recombinant mouse neudesin can bind to heme, whereas
a mutant recombinant mouse neudesin that lacks this putative
heme-binding domain cannot bind to heme (Kimura et al., 2008).
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EXPRESSION
In mouse embryos, neudesin is expressed in several regions; in
particular, it is expressed most abundantly in the developing brain
and spinal cord (Kimura et al., 2005). In the embryonic cerebral
cortex, neudesin is expressed mainly in the preplate, which con-
sists of post-mitotic neural cells after migration, but not in the
subventricular zone and ventricular zone, which consist mainly
of neural progenitor cell/stem cells that are replication compe-
tent (Kimura et al., 2006). Furthermore, in vitro, the expression
of neudesin is gradually reduced after the induction of neurogen-
esis in neural progenitor cells; thereafter, it is hardly expressed in
the early stages of differentiated neurons.
In contrast to the expression pattern in the embryo, neudesin
is abundantly expressed in various tissues—in the adult mouse,
including the brain, heart, lung, and kidney. In the mouse brain,
neudesin is expressed in neurons of every brain region, in partic-
ular in the cerebral cortex, hippocampus, thalamus, and hypotha-
lamus, but it is not expressed in glial cells (Kimura et al., 2005).
These differences in neudesin expression between embryonic-
stage and adult-stage neural cells suggest that neudesin may play
distinct roles in progenitor neural cells and in mature neurons.
SIGNAL TRANSDUCTION
Interestingly, neudesin signal transduction differs among neu-
ral cell types in the central nervous system. The neurotrophic
effects of neudesin in primary cultured neurons are exerted via
the MAPK and PI-3K pathways. In addition, pertussis toxin
(PTX), a Gi/Go protein inhibitor, significantly inhibits the phos-
phorylation of extracellular signal-regulated kinase (ERK)1/2 by
neudesin, indicating that the neurotrophic activity of neudesin
may be related to the activation of a Gi/Go protein-coupled recep-
tor (Kimura et al., 2005). On the other hand, neudesin also
promotes the phosphorylation of ERK, Akt, and cAMP response
element binding protein (CREB) in neural precursor cells; how-
ever, the effect of neudesin is not inhibited by PTX, unlike the case
in primary neurons. In addition, since neudesin increases cAMP
levels in neural precursor cells, the Gs protein-coupled receptor
may be involved in the activation of the MAPK, protein kinase A
(PKA), and PI-3K signaling pathways by neudesin (Kimura et al.,
2006). To date, our group and others have reported that neudesin
activates the MAPK and PI-3K signaling pathways in cancer cells
and in other tissues, besides the nervous system, such as adipose
tissues (Kimura et al., 2009; Han et al., 2012). However, there is
no evidence that neudesin binds directly to these GPCRs of the
G-protein type. Moreover, although neudesin is an extracellular
protein, no specific receptor(s) for neudesin has been reported to
date. Hence, the identification of the neudesin receptor(s), or pro-
teins that interact directly with neudesin, may yield insight into
the neudesin signal transduction system and neudesin function.
FUNCTIONS
With regard to the physiological functions of neudesin in the cen-
tral nervous system, to date, it has been reported that neudesin
acts as a neurotrophic factor in postnatal mature neurons,
enhancing neuronal survival (Kimura et al., 2005), and promotes
cell proliferation and neurogenesis in undifferentiated neural pro-
genitor cells at the embryonic stage (Kimura et al., 2006). In
mouse primary cultured cerebral cortex neurons, recombinant
neudesin significantly increases neuronal survival by decreasing
apoptosis, whereas neudesin exhibited no cell proliferation activ-
ity in mouse primary cultured cerebral cortex astrocytes (Kimura
et al., 2005). This indicates that neudesin, secreted from neu-
rons, acts on these or neighboring neurons, but not on astrocytes.
During brain development, recombinant neudesin increases neu-
ronal numbers directly by inducing the differentiation of neural
precursor cells into microtubule-associated protein 2 (MAP-2)-
positive neurons through the PI-3K and PKA pathways, and
indirectly by transiently promoting the proliferation of the divid-
ing neural precursor cells through the MAPK and PKA pathways,
but not via the PI-3K pathway (Kimura et al., 2006). Similarly,
in Neuro2a cells (mouse neuroblastoma cells), an undifferenti-
ated neural cell line, cell survival, and proliferation were signif-
icantly suppressed by siRNA-mediated knockdown of endoge-
nous neudesin (Kimura et al., 2008). Moreover, interestingly,
a neudesin–hemin complex promoted stronger neuroprotective
activity in primary cultured neurons than did neudesin alone;
similarly, the neudesin–hemin complex, but not neudesin or
hemin alone, induced survival and proliferation in Neuro2a cells
(Kimura et al., 2008). These results indicate that heme binding
to neudesin is essential for the bioactivity of neudesin. However,
it is still not clear by which mechanism heme contributes to the
effects of neudesin. It is possible that the charge of the heme iron
is involved in the binding of neudesin to its receptor, or in the
interactions between neudesin and other proteins. Very recently,
neudesin in the hypothalamus has been reported to modulate
appetite (Byerly et al., 2013). Hypothalamic neudesin mRNA was
regulated by brain-derived neurotrophic factor (BDNF) signal-
ing, an important regulator of appetite. Moreover, recombinant
neudesin that was administered via an interacerebroventricular
cannula decreased food intake and body weight through activa-
tion of melanocortin signaling, by increasing the hypothalamic
Pomc and Mc4r mRNA expression. This is the first report of a
physiological function for neudesin in vivo.
As described above, the secretory heme-binding protein,
neudesin, is highly expressed in the central nervous system, and
functions as a neurotrophic factor to regulate neuronal differenti-
ation and survival by activating the MAPK and PI-3K pathways
in vitro, and as an anorexigenic factor in the hypothalamus
in vivo (Table 1). It is possible that neudesin also plays important
physiological roles in the central nervous system in vivo. The anal-
ysis of the knockout mice will further elucidate its physiological
functions.
DOES NEUDESIN INTERACTWITH THE
PROGESTERONE-SIGNALING PATHWAY?
To date, there is no evidence to support the interaction between
neudesin and progesterone, other than its structural similarity to
PGRMC1, which binds to progesterone with a similar affinity as it
does to other steroids (Meyer et al., 1996). However, previous case
studies of human diseases provide some possible answers to this
question. One case report demonstrated that expression levels of
the progesterone receptor (PR) in estrogen receptor (ER)-positive
breast cancer cells correlated positively with the responsiveness
to tamoxifen, and with the prognosis (Fisher et al., 2001).
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Table 1 | Functions of neudesin.
Neural cell
type or brain
area
Function Signal
transduction
Experimental
method
Mouse neurons Cell survival MAPK and PI3K Addition of
recombinant protein
Mouse neural
precursor cells
Promotion of
neurogenesis
transient cell
proliferation
PI3K
MAPK
Addition of
recombinant protein
Neuro2a cells
(mouse
neuroblastoma)
Cell survival
Cell
proliferation
MAPK and PI3K Addition of
recombinant protein
RNA interference
Mouse
hypothalamus
Suppression
of appetite
− Administration of
recombinant protein
via i.c.v
Intriguingly, neudesin protein was also upregulated in ER+/PR+
tumors, compared with ER+/PR− tumors (Neubauer et al.,
2006). These reports raise the possibility that neudesin also inter-
acts with progesterone, and is associated with the pharmacologi-
cal effect of tamoxifen.
In addition to the fact that the PGRMC1 complex binds to pro-
gesterone, Liu et al. showed that the growth effect of progesterone
on neural precursor cells is mediated by membrane-associated
PGRMC1 and PGRMC2, via activation of the MAPK pathway,
as in the case of neudesin (Kimura et al., 2006; Liu et al., 2009).
Furthermore, progesterone was reported to directly and rapidly
inhibit GnRH neuronal activity via PGRMC1 (Bashour and
Wray, 2012). These reports suggest that PGRMCs are membrane
receptors for progesterone, and are involved in immediate-type
reactions to progesterone. Moreover, it has been reported that
progesterone binds directly to PGRMC1 (Peluso et al., 2008). On
the other hand, other reports suggest that PGRMC1 is indirectly
related to progesterone activity because of adrenal steroidogene-
sis, but it does not bind directly to progesterone (Min et al., 2005).
Nevertheless, PGRMC1 is closely involved in cellular responses
to progesterone. If future research reveals an interaction between
neudesin and progesterone, this could provide the missing link
regarding to the progesterone activity.
Interestingly, neudesin is a secretory protein, unlike PGRMC1.
Since progesterone is lipophilic, the consensus model for the
mechanism of progesterone activity holds that the steroid hor-
mone penetrates the plasma membrane and gains access to
classical nuclear PRs in order to exert its biological functions.
However, it is assumed that the “rapid effects” of progesterone
depend upon interactions with certain cell surface molecules. It
is then not clear why such a lipophilic molecule is trapped on
the cell surface, without penetrating the plasma membrane into
the cytoplasm, and whether this occurs accidentally. It is possible
that progesterone binds to proteins that negate its liposolubility,
thus overcoming this problem. Neudesin may function as such
a progesterone-binding protein in the extracellular environment.
Formation of a progesterone–neudesin complex may suppress the
transference of progesterone to its nuclear receptor; alternatively,
the complexmay act on a cell surface protein, such as an unknown
PR (Figure 1D). The elucidation of the novel mechanisms regu-
lating the neudesin-mediated progesterone effects will present a
breakthrough in sex steroid hormone research in the future.
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